- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Advanced International Federation of Gynecology and Obstetrics (FIGO) Stage IIIB, IIIC or Stage IV epithelial ovarian, fallopian tube or primary peritoneal cancer; Advanced carcinoma of cervix; Relapsed or recurrent glioblastoma; Stage IV (metastatic) non-small cell lung cancer (NSCLC); Metastatic colorectal cancer.
- Meeting Date: July 2020
- Public Summary Document (PSD) July 2020 PBAC Meeting - (PDF 804KB)
- Public Summary Document (PSD) July 2020 PBAC Meeting - (Word 43KB)
Bevacizumab – July 2020
Bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V infusion 400 mg in 16 mL; Zirabev®
Last updated
30 October 2020